SCHEMBL2165350

SCHEMBL2165350

Cc1ccc(CC(O)C(=O)O)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.56
CCR2 P41597 1/20 0.46
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 2/20 0.41
EPHX2 P34913 1/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
RAB9A P51151 2/20 0.41
MAPK1 P28482 1/20 0.41
KMO O15229 1/20 0.41
AGTR1 P30556 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 1/20 0.39
PNMT P11086 1/20 0.39
LDHA P00338 1/20 0.38
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2165343 1.00 KDM6B (0.56) KDM6BCCR2KDM4ENPSR1ALDH1A1
SCHEMBL2164411 0.84 KDM6B (0.61) KDM6BCCR2KMOPNMT
SCHEMBL2164417 0.84 KDM6B (0.61) KDM6BCCR2KMOPNMT
SCHEMBL2165036 0.83 HPGD (0.44) KDM4ENPSR1ALDH1A1EPHX2GAA
SCHEMBL25804686 0.81 KDM6B (0.72) KDM6BKDM4EALDH1A1GAAMAPT
SCHEMBL2164021 0.80 KDM6B (0.56) KDM6BKDM4EALDH1A1GAAMAPT
SCHEMBL2164014 0.80 KDM6B (0.56) KDM6BKDM4EALDH1A1GAAMAPT
SCHEMBL31267271 0.80 KDM4E (0.47) CCR2KDM4ENPSR1EPHX2GAA
SCHEMBL12656383 0.80 KDM4E (0.47) CCR2KDM4ENPSR1EPHX2GAA
SCHEMBL31303979 0.80 KDM4E (0.47) CCR2KDM4ENPSR1EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985747-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-26 US disclosed
US-20100249114-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-30 US disclosed
US-20100234361-A1 SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-16 US disclosed
US-7700598-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-20 US disclosed
US-7696196-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-13 US disclosed
US-20090176770-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-09 US disclosed
US-20090111797-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-30 US disclosed
US-7491717-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-17 US disclosed
US-7479488-B2 Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-20 US disclosed
CN-1976916-A Selected CGRP-antagonists, method for the production thereof and their use as medicaments BOEHRINGER INGELHEIM INT (DE) 2007-06-06 CN disclosed
US-20060252750-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176770-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM6B 4577/4885CCR2 750/4885KDM4E 3751/4885
US-20060252750-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM6B 4577/4885CCR2 750/4885KDM4E 3751/4885
US-20090111797-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM6B 4577/4885CCR2 750/4885KDM4E 3751/4885
US-20100249114-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM6B 4577/4885CCR2 750/4885KDM4E 3751/4885
US-20100234361-A1 SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, CALCA KDM6B 4577/4885CCR2 750/4885KDM4E 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.